Gilead Sciences reported $-6.75 in EPS Earnings Per Share for its fiscal quarter ending in June of 2026.


Fiscal Calendar Actual Consensus Previous Date
FY2026Q3 Sep/2025 2.23 2.47 Oct/22
FY2026Q2 Jun/2026 -6.75 -7.32 2.01 Aug/04
FY2026Q1 Mar/2026 2.03 1.9 1.81 May/07
FY2025Q4 Dec/2025 1.86 1.89 1.90 Feb/10
FY2025Q3 Sep/2025 2.47 2.16 2.02 Oct/30




Eps Change Date
AbbVie USD 3.65 1 Jun/2026
Agios Pharmaceuticals USD -1.69 0 Jun/2026
ALKERMES USD 0 0.4 Jun/2026
Alnylam Pharmaceuticals USD 1.84 0.15 Jun/2026
Amgen USD 6.29 1.14 Jun/2026
Biogen USD 3.6 0.03 Jun/2026
BioMarin Pharmaceutical USD 1.2 0.44 Jun/2026
Bristol-Myers Squibb USD 2.04 0.46 Jun/2026
Coherus Biosciences USD -0.43 0.06 Dec/2025
Eli Lilly USD 8.38 0.17 Jun/2026
Gilead Sciences USD -6.75 8.78 Jun/2026
GlaxoSmithKline GBP 0.51 0.08 Jun/2026
Glaxosmithkline GBP 0.62 0.41 Mar/2026
Incyte USD 3.09 1.28 Jun/2026
J&J USD 2.9 0.2 Jun/2026
Merck USD -0.13 1.15 Jun/2026
Moderna USD -1.97 1.43 Jun/2026
Neurocrine Biosciences USD 2.85 0.91 Jun/2026
Novartis USD 2.41 0.42 Jun/2026
Pfizer USD 0.77 0.02 Jun/2026
PTC Therapeutics USD 0.92 0.95 Jun/2026
Puma Biotechnology USD 0.41 0.5 Sep/2024
Regeneron Pharmaceuticals USD 14.29 4.82 Jun/2026
Sangamo BioSciences USD -0.18 0.1 Jun/2024
Sanofi EUR 2.09 0.21 Jun/2026
Sarepta Therapeutics USD 0.64 2.52 Jun/2026
United Therapeutics USD 7.27 1.45 Jun/2026
Vertex Pharmaceuticals USD 4.73 0.26 Jun/2026